Remdesivir (Veklury): What you should know
Many potential drugs and vaccines for use against COVID-19 are being evaluated in Canada and around the world. We’re closely tracking all potential drugs and vaccines in development.
You can search the complete list of applications received for COVID-19-related drugs and vaccines and their status.
About remdesivir (Veklury)
Remdesivir (brand name Veklury) is an antiviral drug used to treat patients with severe symptoms of COVID-19, who need extra oxygen to help them breathe. It’s used in health care facilities such as hospitals, as it’s given via infusion into the veins of patients.
Given the emergency context of COVID-19, Health Canada conducted an expedited review to address the urgent need for treatment options. Based on this review, Health Canada authorized remdesivir with conditions in July 2020. It’s sold in Canada by Gilead Sciences Canada, Inc.
Remdesivir is authorized for use in adults and youth aged 12 years and older who weigh at least 40 kg. Gilead Sciences Canada, Inc. did not seek authorization to use remdesivir to treat children or pregnant women.
Find detailed technical information about remdesivir, such as the product monograph and our regulatory decision summary, in the COVID-19 vaccines and treatments regulatory portal.
- Notice prescription drug list for remdesivir
- Update on remdesivir: continued monitoring
- Importation of U.S. clinical trial-labelled remdesivir for injection due to shortage of Canadian-labelled remdesivir
- List of authorized drugs, vaccines and expanded indications for COVID-19
- Vaccines and treatments for COVID-19
Report a problem or mistake on this page
- Date modified: